GCCL, a leading global clinical trial specimen analysis organization, announced on Tuesday that it participated as a platinum sponsor in the Asia Bio Partnering Forum 2026 (ABP 2026) in Singapore from August 31 to September 2. The company leveraged this opportunity to expand its global collaboration network and strengthen its presence in the Asia-Pacific region.
ABP 2026 is a premier bio-partnering event that brings together global pharmaceutical and biotech companies, investors, and life sciences professionals, primarily from the Asia-Pacific region. This year’s event attracted over 650 industry experts and facilitated approximately 2,500 one-on-one partnering meetings.
At the forum, GCCL engaged in strategic partnering meetings with global pharmaceutical and biotech companies, as well as contract research organizations (CROs). The company also explored potential collaborations with local Singaporean firms and institutions. GCCL particularly focused on identifying cooperation opportunities in specimen analysis and assay development with companies developing various novel drug modalities, aiming to solidify its foothold in the Asia-Pacific market.
GCCL sponsored the official welcome reception preceding the main event. Choi Yoo-hwa, head of GCCL’s Business Operations Division, delivered a keynote speech on behalf of the sponsors, highlighting GCCL’s expertise in clinical trial specimen analysis and outlining its strategy for supporting global clinical development.
During the forum, GCCL held high-level meetings with Singapore-based global pharmaceutical and diagnostic companies, as well as clinical trial service providers. Discussions with global CRO executives centered on sharing information about their respective services, reviewing existing collaborations, and exploring avenues for expanding future partnerships.
The company also met with representatives from Singapore’s government economic development agency to discuss potential collaborations in supporting local biotech firms’ drug development efforts, thereby strengthening its ties within the region’s biotech ecosystem.
GCCL showcased its comprehensive specimen analysis services and cutting-edge assay development capabilities through a dedicated exhibition booth at the venue. The company’s offerings support the entire spectrum of clinical trials, from early-phase studies to late-stage development.
Throughout the event, GCCL engaged in partnership discussions with pharmaceutical and biotech firms, as well as related organizations from diverse regions, including South Korea, China, Japan, Singapore, Vietnam, and Europe. These talks focused on addressing the demand for specimen analysis and exploring collaboration opportunities across various innovative drug modalities, such as mRNA therapeutics, nucleic acid-based treatments, radiopharmaceuticals, and antibody-based therapies.
Choi remarked that this event provided an invaluable platform for direct engagement with Asia-Pacific drug developers. It gained crucial insights into the specimen analysis needs for various novel drug modalities and had productive discussions about concrete collaboration opportunities with global partners. Moving forward, they’re committed to further expanding the partnerships with global CROs and integrating more deeply into the local biotech ecosystem.
In recent months, GCCL has been actively expanding its reach within the domestic and international pharmaceutical and biotech sectors to grow its clinical trial specimen analysis business. Last month, the company hosted a clinical development analysis strategy seminar for biotech startups at the Seoul Bio Hub. GCCL has also participated in major industry events such as the Global Bio Conference (GBC) and the ADC Conference, further cementing its position as a key player in the field.